Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Mai 2019 18:20 ET | Quelle: Novartis Pharma AG

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline...
08. Mai 2019 01:15 ET | Quelle: Novartis Pharma AG

Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS

Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive...
07. Mai 2019 13:55 ET | Quelle: Novartis Pharma AG

New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with...
07. Mai 2019 01:15 ET | Quelle: Novartis Pharma AG

Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS

Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or...
05. Mai 2019 11:30 ET | Quelle: Novartis Pharma AG

AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)...
02. Mai 2019 16:30 ET | Quelle: Novartis Pharma AG

Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN

After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study...
30. April 2019 16:30 ET | Quelle: Novartis Pharma AG

New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions

Novartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple...
30. April 2019 01:15 ET | Quelle: Novartis Pharma AG

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement,...
24. April 2019 01:00 ET | Quelle: Novartis Pharma AG

Novartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben

Die Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2] ...
24. April 2019 01:00 ET | Quelle: Novartis Pharma AG

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by...

Vorherige Seite

Nächste Seite